Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Empirical Finance LLC

Empirical Finance LLC cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,821 shares of the life sciences company’s stock after selling 139 shares during the quarter. Empirical Finance LLC’s holdings in Illumina were worth $644,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Empowered Funds LLC increased its position in shares of Illumina by 9.7% during the fourth quarter. Empowered Funds LLC now owns 4,344 shares of the life sciences company’s stock valued at $580,000 after acquiring an additional 384 shares during the last quarter. Golden State Wealth Management LLC purchased a new position in shares of Illumina during the 4th quarter worth approximately $32,000. Lecap Asset Management Ltd. acquired a new stake in Illumina in the 4th quarter valued at approximately $2,846,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in Illumina by 116.9% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after purchasing an additional 466,519 shares during the last quarter. Finally, Strategic Financial Concepts LLC purchased a new stake in Illumina in the fourth quarter valued at approximately $1,464,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Trading Down 5.5 %

Shares of Illumina stock opened at $104.99 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company has a market capitalization of $16.65 billion, a P/E ratio of -13.67 and a beta of 1.10. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66. The company’s fifty day moving average is $136.70 and its two-hundred day moving average is $135.56.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Analysts forecast that Illumina, Inc. will post 4.42 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group dropped their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the company from $177.00 to $140.00 in a report on Friday. Finally, Leerink Partners increased their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $160.15.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.